Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JY231 Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia - A Safety, Tolerability, and Efficacy Study

NCT06678282 is registered in ClinicalTrials.gov with Shenzhen Genocury Biotech Co., Ltd. as lead sponsor.

NCT NCT06678282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06678282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JY231 Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia - A Safety, Tolerability, and Efficacy Study
Lead sponsor
Shenzhen Genocury Biotech Co., Ltd.
Phase
Not applicable
Overall status
Recruiting
Start date
September 7, 2023
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-all, b-nhl